SSC
NVO

Syverson Strege & Co’s Novo Nordisk NVO Stock Holding History

Syverson Strege & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-870
Closed -$69.2K – 431
2023
Q1 		$69.2K Buy
+870
New +$61.7K 0.03% 107
2021
Q4 		– Sell
-510
Closed -$24K – 428
2021
Q3 		$24K Buy
+510
New +$24.7K 0.02% 179

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Syverson Strege & Co's NVO Position: Q2 2023 in Review

Syverson Strege & Co sold out of Novo Nordisk (NVO) in Q2 2023, closing a stake of 870 shares — an estimated $69.2K sold.

Syverson Strege & Co first reported a position in NVO in Q3 2021 and held it in 2 quarters. The position peaked at $69.2K in Q1 2023. 1,197 funds tracked by Wall St. Rank hold NVO as of Q2 2023.

  • Syverson Strege & Co reported no remaining Novo Nordisk position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 870 Novo Nordisk shares in Q2 2023, an estimated $69.2K.
  • Syverson Strege & Co first reported a position in Novo Nordisk in Q3 2021 and held it in 2 quarters.
  • Syverson Strege & Co's Novo Nordisk position peaked at $69.2K in Q1 2023.
  • 1,197 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.